IL22 and inflammatory bowel disease: In contrast, in Caco-2/PBMCs, IL-22 increased upon treatment with MH002 cell-free supernatant but showed an IBD stool background-dependent effect in the IBD-M-SHIME® experiment, thereby suggesting either cell-specific effects (local vs. periphery) or a distinct regulation of IL-22 by microbiome-derived products.